Stock Quote
Novartis AG (NOVN.VX) (Virt-X Level 1)
CHF55.15
23 Nov 2009
+2.22%
CHF53.95
CHF54.30
5,829,183
CHF55.50
CHF54.25
CHF58.30
CHF39.08
0.76
5,034,829
No news stories for this company within the last 30 days.
NOVN.VX
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Vasella, Daniel | Chairman of the Board, Chief Executive Officer | 3,315,778 |
| Lehner, Ulrich | Independent Non-Executive Vice Chairman of the Board, Lead Director | 1,050,000 |
| Rudloff, Hans-Joerg | Non-Executive Vice Chairman of the Board, Independent Non-Executive Director | 736,337 |
Profile
Novartis AG is a Switzerland-based holding that, through its subsidiaries, is engaged in the research, development, manufacture and marketing of healthcare products. The Company’s healthcare solutions portfolio includes medicines, preventive vaccines and diagnostic tools, generic pharmaceuticals and... Full Description
Company Address
Novartis AG
Lichtstrasse 35
Basel 4022
Lichtstrasse 35
Basel 4022
Analyst Research
| NOVN.VX | Industry | |
|---|---|---|
| P/E(TTM) | 15.91 | 6.90 |
| P/S(TTM) | 2.84 | 1.54 |
| ROI(TTM) | 11.33 | 6.18 |
| ROE(TTM) | 14.59 | 9.32 |
| Consensus Recommendation | Outperform |
|---|---|
| EPS Est. (Current Period) | -- |
| EPS Est. (Current Year) | -- |
| Total Revenue | $11,510.72M |
| Net Income | $2,153.29M |
| EPS | $0.94 |
